Kim Chi

3.4k total citations
49 papers, 1.9k citations indexed

About

Kim Chi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Kim Chi has authored 49 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 14 papers in Cancer Research. Recurrent topics in Kim Chi's work include Prostate Cancer Treatment and Research (29 papers), Radiopharmaceutical Chemistry and Applications (11 papers) and Cancer, Lipids, and Metabolism (10 papers). Kim Chi is often cited by papers focused on Prostate Cancer Treatment and Research (29 papers), Radiopharmaceutical Chemistry and Applications (11 papers) and Cancer, Lipids, and Metabolism (10 papers). Kim Chi collaborates with scholars based in Canada, United States and United Kingdom. Kim Chi's co-authors include Martin Gleave, Amina Zoubeidi, Scott Tyldesley, Hideaki Miyake, Tobias Zellweger, Alan So, Satoshi Kiyama, Peter Venner, Fred Saad and Anthony W. Tolcher and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Kim Chi

47 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kim Chi Canada	20	872	799	636	520	291	49	1.9k
Isabel Heidegger Austria	26	829 1.0×	1.2k 1.5×	553 0.9×	554 1.1×	489 1.7×	123	2.4k
Vladimir Bilim Japan	25	1.4k 1.6×	475 0.6×	583 0.9×	397 0.8×	255 0.9×	81	2.1k
Christian Wülfing Germany	22	629 0.7×	786 1.0×	508 0.8×	356 0.7×	634 2.2×	113	1.9k
Donghua Yin United States	24	813 0.9×	582 0.7×	584 0.9×	361 0.7×	161 0.6×	45	2.1k
Dingwei Ye China	29	1.1k 1.3×	1.0k 1.3×	501 0.8×	874 1.7×	401 1.4×	114	2.3k
John C. Araujo United States	25	851 1.0×	1.4k 1.8×	1.1k 1.7×	567 1.1×	134 0.5×	89	2.5k
Lydia Nakopoulou Greece	27	1.0k 1.2×	400 0.5×	863 1.4×	684 1.3×	330 1.1×	79	2.3k
Akihiko Shimomura Japan	22	751 0.9×	536 0.7×	1.1k 1.7×	537 1.0×	137 0.5×	132	2.0k
Jozien Helleman Netherlands	22	1.1k 1.2×	457 0.6×	566 0.9×	670 1.3×	139 0.5×	42	2.0k
Raffael Kurek Germany	18	963 1.1×	721 0.9×	1.0k 1.6×	563 1.1×	129 0.4×	39	2.2k

Countries citing papers authored by Kim Chi

Since Specialization

Citations

This map shows the geographic impact of Kim Chi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim Chi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim Chi more than expected).

Fields of papers citing papers by Kim Chi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kim Chi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim Chi. The network helps show where Kim Chi may publish in the future.

Co-authorship network of co-authors of Kim Chi

This figure shows the co-authorship network connecting the top 25 collaborators of Kim Chi. A scholar is included among the top collaborators of Kim Chi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kim Chi. Kim Chi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

So, Alan, Kim Chi, Brita Danielson, et al.. (2025). 2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castrationsensitive prostate cancer (Update). Canadian Urological Association Journal. 19(5). E142–52.

Nip, Ka Mun, Arman Rahmim, Robert H. Bell, et al.. (2025). Machine Learning Model Integrating Computed Tomography Image–Derived Radiomics and Circulating miRNAs to Predict Residual Teratoma in Metastatic Nonseminoma Testicular Cancer. JCO Clinical Cancer Informatics. 9(9). e2500105–e2500105. 1 indexed citations

Roubaud, Guilhem, Gerhardt Attard, Martin Boegemann, et al.. (2024). Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer. European Journal of Cancer. 209. 114183–114183. 2 indexed citations

Armstrong, Andrew J., Oliver Sartor, Johann S. de Bono, et al.. (2024). Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial. European Urology. 86(6). 552–562. 7 indexed citations

Merseburger, Axel S., Anders Bjartell, Hirotsugu Uemura, et al.. (2024). Targeted Investigational Treatment Analysis of Novel Anti‐androgen (TITAN) study: ultralow prostate‐specific antigen decline with apalutamide plus androgen‐deprivation therapy. British Journal of Urology. 134(6). 982–991. 8 indexed citations

So, Alan, Kim Chi, Brita Danielson, et al.. (2022). UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer. Canadian Urological Association Journal. 16(12). E581–E589. 8 indexed citations

T’jollyn, Huybrecht, Caly Chien, Angela Lopez‐Gitlitz, et al.. (2022). Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study. Cancer Chemotherapy and Pharmacology. 89(5). 629–641. 10 indexed citations

Selvarajah, Shamini, Kasmintan A. Schrader, Michael Kolinsky, et al.. (2022). Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in Canada. Canadian Urological Association Journal. 16(10). 321–332. 5 indexed citations

Hadaschik, Boris, Frederik L. Giesel, & Kim Chi. (2020). Prostate-specific Membrane Antigen Imaging and Theranostics Impact Patient Outcomes. European Urology Focus. 7(2). 229–230. 2 indexed citations

10.

Malone, Shawn, Bobby Shayegan, Naveen S. Basappa, et al.. (2019). Management algorithms for metastatic prostate cancer. Canadian Urological Association Journal. 13(12). 50–60. 4 indexed citations

11.

Rousseau, Étienne, Don Wilson, Andra Krauze, et al.. (2019). A Prospective Study on ¹⁸F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer. Journal of Nuclear Medicine. 60(11). 1587–1593. 81 indexed citations

12.

So, Alan, Kim Chi, Brita Danielson, et al.. (2019). Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer. Canadian Urological Association Journal. 14(2). 19 indexed citations

13.

Chi, Kim & Fred Saad. (2017). New research in prostate cancer, ASCO-GU 2017. Canadian Urological Association Journal. 11(6S3). 166–166. 2 indexed citations

14.

Wu, Jackson, Daniel Y.C. Heng, Scott North, et al.. (2014). A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration resistant prostate cancer. Canadian Urological Association Journal. 8(9-10). 583–583. 5 indexed citations

15.

Shiota, Masaki, Jennifer L. Bishop, Ka Mun Nip, et al.. (2013). Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate Cancer. Cancer Research. 73(10). 3109–3119. 159 indexed citations

16.

Saad, Fred, Sébastien J. Hotte, Scott North, et al.. (2011). Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c. Clinical Cancer Research. 17(17). 5765–5773. 96 indexed citations

17.

Gleave, Martin, Hideaki Miyake, & Kim Chi. (2005). Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemotherapy and Pharmacology. 56(S1). 47–57. 34 indexed citations

18.

Tolcher, Anthony W., Kim Chi, John G. Kuhn, et al.. (2005). A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer. Clinical Cancer Research. 11(10). 3854–3861. 123 indexed citations

19.

Gleave, Martin, Colleen C. Nelson, & Kim Chi. (2003). Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer. Current Drug Targets. 4(3). 209–221. 20 indexed citations

20.

Gleave, M.E., et al.. (2001). Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology. 58(2). 39–48. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact